This file is part of IDEAS, which uses RePEc data


[ Papers | Articles | Software | Books | Chapters | Authors | Institutions | JEL Classification | NEP reports | Search | New papers by email | Author registration | Rankings | Volunteers | FAQ | Blog | Help! ]

The Cost of Disability and Medically Related Absenteeism Among Employees with Multiple Sclerosis in the US

Author info | Abstract | Publisher info | Download info | Related research | Statistics
Author Info
Jasmina I. Ivanova (Analysis Group, Inc., New York, New York, USA)
Howard G. Birnbaum (Analysis Group, Inc., Boston, Massachusetts, USA)
Seth Samuels (Analysis Group, Inc., New York, New York, USA)
Matthew Davis (Analysis Group, Inc., Boston, Massachusetts, USA)
Amy L. Phillips (EMD Serono, Inc., Rockland, Massachusetts, USA)
Dennis Meletiche (EMD Serono, Inc., Rockland, Massachusetts, USA)
Abstract

Background: Studies have not previously reported the indirect cost burden of multiple sclerosis (MS) from an employer perspective. Objective: To compare annual indirect costs between privately insured US employees with MS and matched employee controls. Methods: A retrospective analysis of a privately insured claims database containing disability data from 17 US companies was conducted. Employees with ≥1 MS diagnosis (ICD-9-CM: 340.x) after 1 January 2002, aged 18-64 years, were selected. Employees with MS were matched by age and sex to employee controls without MS. All were required to have continuous health coverage 3 months before MS diagnosis (baseline) and 12 months after (study period). Main outcomes measures included study period annual indirect (disability and medically related absenteeism) costs. For completeness, we also included measures of direct (medical and drug) costs. Chi-squared tests were used to compare baseline co-morbidities and differences in indirect resource use (disability and medically related absenteeism) between employees with MS and controls. Wilcoxon rank-sum tests were used for univariate comparisons of disability and medically related absenteeism days and associated annual indirect and direct costs between employees with MS and controls. Generalized linear models, controlling for differences in baseline characteristics, were used to estimate risk-adjusted annual costs for employees with MS and controls. Results: Employees with MS (n - 989) averaged 44 years of age, and 66% were female. Compared with employee controls, employees with MS had significantly higher rates of mental health disorders, other neurological disorders and physical disorders measured by the Charlson Co-morbidity Index. Employees with MS were more likely to have short-term or long-term disability than employee controls (21.4% vs 5.2%, respectively; p < 0.0001), resulting in a higher mean number of disability days per year (29.8 vs 4.5; p < 0.0001). Employees with MS also had a higher rate of medically related absenteeism and associated absenteeism days than employee controls. On average, annual costs (year 2006 values) for disability were significantly higher for employees with MS ($US3868) than employee controls ($US414; p < 0.0001). Annual medically related absenteeism costs were also higher for employees with MS than for controls ($US1901 vs $US1003, respectively; p < 0.0001). On average, total annual indirect costs for employees with MS were $US5769 compared with $US1417 for controls (p < 0.0001). Conclusions: MS is a chronic and debilitating disease that poses a substantial employer burden in terms of medically related absenteeism and disability costs. Indirect costs of employees with MS were >4 times those of employee controls.

Download Info
To download:

If you experience problems downloading a file, check if you have the proper application to view it first. Information about this may be contained in the File-Format links below. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.

File URL: http://PharmacoEconomics.adisonline.com/pt/re/phe/pdfhandler.00019053-200927080-00006.pdf
File Format: application/pdf
File Function:
Download Restriction: Pay per view
File URL: http://PharmacoEconomics.adisonline.com/pt/re/phe/fulltext.00019053-200927080-00006.htm
File Format: text/html
File Function:
Download Restriction: Pay per view

As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.

Publisher Info
Article provided by Wolters Kluwer Health | Adis in its journal PharmacoEconomics.

Volume (Year): 27 (2009)
Issue (Month): 8 ()
Pages: 681-691
Download reference. The following formats are available: HTML (with abstract), plain text (with abstract), BibTeX, RIS (EndNote, RefMan, ProCite), ReDIF
Handle: RePEc:wkh:phecon:v:27:y:2009:i:8:p:681-691

Contact details of provider:
Web page: http://pharmacoeconomics.adisonline.com/

For technical questions regarding this item, or to correct its listing, contact: (Remco Bouckaert).

Related research
Keywords:

Find related papers by JEL classification:
C - Mathematical and Quantitative Methods
D - Microeconomics
I - Health, Education, and Welfare
Z - Other Special Topics
I1 - Health, Education, and Welfare - - Health
I19 - Health, Education, and Welfare - - Health - - - Other
I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets

Statistics
Access and download statistics

Did you know? You too can volunteer for RePEc, for example by providing information about publications in your institution.

This page was last updated on 2009-11-13.


This information is provided to you by IDEAS at the Department of Economics, College of Liberal Arts and Sciences, University of Connecticut using RePEc data on a server sponsored by the Society for Economic Dynamics.